A: Elbow splint. B: Left wrist splint with reinforcing plastic strip arrowed.
hours before a severe to incapacitating headache. .Each patient was studied during four consecutive (imminent) attacks, two of which were treated prophylactically with domperidone and two with a placebo under double-blind randomised conditions. The patients were given either three 10 mg domperidone tablets or three matching placebo tablets as soon as they became aware of the warning symptoms.
No aura or headache was experienced in 25 out of the 38 (66%) attacks when domperidone was taken and in only two out of the 38 (5 %) after the placebo (table) . Ten patients, in whom the placebo failed twice to prevent an attack, had no attack on two occasions when treated with domperidone. In all but one patient the attacks were as severe as usual when treated prophylactically with the placebo. The effects of domperidone were not related to either the type of warning symptoms or to the time lag before the actual attack. There were no side effects.
Number of patients with complete classical migraine experiencing attacks after prophylactic treatment with domperidone 30 mg and placebo (n= 19) No of attacks after administration of: Domperidone Placebo Statistically significant difference between drug and placebo, p<<0001 (Wilcoxon's matchedpairs signed ranks test).
Comment I know of no investigators who have tried to prevent migraine attacks in patients with early warning phenomena. The present findings show, however, that this can be achieved in most cases with a relatively high dose of domperidone. How domperidone acts in this condition is nevertheless not known. Since it does not cross the bloodbrain barrier4 its effects are unlikely to be mediated by the central nervous system, unless patients with migraine have a defective barrier.5 As it is a potent dompamine-antagonist domperidone would, however, provoke extrapyramidal symptoms if the blood-brain barrier was defective; no such problems have been reported in patients with migraine. Thus, domperidone probably does not act on the central nervous system, which is often thought to play a part in the pathogenesis of migraine. Whatever the mechanism domperidone, paradoxically, prevents migraine attacks when it is taken up to 48 hours before the attack even though its duration of action is about six hours. Thus, thorough investigation of patients with complete migraine during the day before an attack should give more information on the pathogenesis of the disease. 
